Abstract: The purpose of the present invention is to provide a myopia prevention device. A myopia prevention device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia. Further, a myopia prevention device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia.

Abstract: A wavelength-selective transmissive glass has a light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance T315 nm or less at a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ak is a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tk is a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm: Tmore than 315 nm and 400 nm or less=(?k=more than 315400 Ak×Tk)/(?k=more than 315400 Ak) T315 nm or less=(?k=300315 Ak×Tk)/(?k=300315 Ak).

Abstract: To provide an irradiation device capable of preventing myopia or slowing the progression of myopia by the action of light irradiated toward the eyeball. An irradiation device (10) comprises a light source (1) and an instrument (2) on which the light source (1) is mounted. The light source (1) emits at least light having a wavelength within a range of 350 to 400 nm, inclusive, and is disposed in a position that allows irradiation in an eyeball direction when the instrument (2) is mounted. Further, the light source (1) is disposed in a position 0 to 100 mm, inclusive, from a surface of the eyeball. At this time, an irradiance of the light having a wavelength within the range of 350 to 400 nm, inclusive, is 0.02 to 1.0 W/m2, inclusive, on the eyeball surface when the instrument (2) is worn.

Abstract: A wavelength-selective transmissive glass article has light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less of 1% or more. In addition, the wavelength-selective transmissive glass article has light transmittance T315 nm or less at a wavelength of 315 nm or less of 60% or less.

Abstract: A pharmaceutical composition for prophylaxis and/or treatment of a corneal and conjunctival disease or presbyopia, the composition containing a compound represented by Formula (I), or a salt thereof or a prodrug thereof as an active ingredient, wherein m and n are each independently an integer of 0 to 5; m+n?1; and each aromatic ring of the compound represented by Formula (I) may be substituted.

Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Abstract: The present invention aims to provide an agent for treating meibomian gland dysfunction. The present invention provides an agent for treating meibomian gland dysfunction, which contains activated vitamin D3 or a derivative thereof as an active ingredient.

Abstract: The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.

Abstract: The present invention provides compositions incorporating lactic acid bacteria or bifidobacteria with components that act to enhance the function of lactic acid bacteria or bifidobacteria. The present invention relates to a composition containing at least one component selected from the group consisting of lutein, fish oil, lactoferrin, vitamins, ?-aminobutyric acid, and zinc, and a strain of lactic acid bacteria or bifidobacteria.

Abstract: The present invention provides a crystalline lens hardening inhibitor, containing a compound represented by the formula (I): wherein R1-R4 are the same or different and each is a hydrogen atom, a halogen atom, a hydroxy group, a sulfanyl group, a lower alkyl group, a lower acyl group, a lower alkoxy group, a carboxyl group, a carbamoyl group or a carbonylamino acid group, or a salt thereof, and/or a compound represented by the formula (II): wherein R is a hydrogen atom, or a lower alkyl group optionally substituted by an amino group, a hydroxy group, a sulfanyl group or a carboxyl group, and A is a lower alkylene group, or a salt thereof.

Abstract: A pharmaceutical composition for prophylaxis and/or treatment of a corneal and conjunctival disease or presbyopia, the composition containing a compound represented by Formula (I), or a salt thereof or a prodrug thereof as an active ingredient, wherein m and n are each independently an integer of 0 to 5; m+n?1; and each aromatic ring of the compound represented by Formula (I) may be substituted.

Abstract: The purpose of the present invention is to provide a myopia prevention device. A myopia prevention device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia. Further, a myopia prevention device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia.

Abstract: The present invention aims to provide an agent for treating meibomian gland dysfunction. The present invention provides an agent for treating meibomian gland dysfunction, which contains activated vitamin D3 or a derivative thereof as an active ingredient.

Abstract: A noninvasive method for measuring biological materials which is configured to enable an immediate diagnosis is used in an analytical absorption spectroscopy apparatus including a broadly tunable infrared laser oscillation device, a photodetection device, and an analysis device. The method applies an infrared ray to an analyte organism while tuning the wavelength from the laser oscillation device with or without the ray going through a nonlinear optical device. The photodetection device detects a reflected beam, a transmitted beam, or a scattering beam from the organism or ultrasound generated within the organism by using the detection device. The analysis device analyzes a signal input by the photodetection device.

Abstract: The invention provides a method of efficiently producing corneal endothelial cells, particularly from corneal stroma or iPS cell-derived neural crest stem cells, a method of producing corneal endothelial cells stably in a large amount by inducing more efficient differentiation of stem cells into corneal endothelial cells, and a medicament containing corneal endothelial cells. The method of inducing differentiation of stem cells into corneal endothelial cells includes a step of culturing the stem cells in a differentiation induction medium containing a GSK3 inhibitor (preferably a GSK3? inhibitor) and retinoic acid, with the differentiation induction medium preferably further containing one or more of TGFb2, insulin, a ROCK inhibitor, and the like.

Abstract: The present invention provides an effective and safe prophylactic and therapeutic pharmaceutical agent and supplement for corneal epithelium disorders and/or conjunctival epithelial disorders. This is a therapeutic and/or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelial disorders comprising eicosapentaenoic acid and/or docosahexaenoic acid, a glycerin ester or phospholipid comprising these fatty acids as constituent fatty acids, or a lower alcohol ester of these fatty acids as active ingredients. These preferably comprise EPA and/or DHA in the form of a refined fish oil or refined krill oil. A total of at least approximately 50 to 5,000 mg of EPA and/or DHA or the esters thereof are taken daily, thereby easing corneal epithelium disorders and/or conjunctival epithelial disorders. In addition, the amount of tears may be recovered.

Abstract: The present invention provides a method of measuring the elasticity of crystalline lens and an apparatus for measuring the elasticity of the crystalline lens for measuring stiffness of the crystalline lens 1, wherein the crystalline lens 1 is irradiated with pulse laser light to generate photoelastic waves from the crystalline lens 1, and the photoelastic waves from the crystalline lens 1 are measured.

Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Abstract: The present invention provides a method of measuring the elasticity of crystalline lens and an apparatus for measuring the elasticity of the crystalline lens for measuring stiffness of the crystalline lens 1, wherein the crystalline lens 1 is irradiated with pulse laser light to generate photoelastic waves from the crystalline lens 1, and the photoelastic waves from the crystalline lens 1 are measured.

Abstract: In a laser scanning method for measuring in vivo substances, wavelength of the anti-Stokes line is made greater than wavelength absorption band of the specific substance, the wavelength of the probe light is shifted from the wavelength of the anti-Stokes line by a shift amount of Raman scattering of the specific substance, and the wavelength of the Stokes light is shifted from the wavelength of the probe light by the shift amount of the Raman scattering of the specific substance. According to this, density (concentration and distribution) of lutein in an eye fundus is measured quantitatively and non-invasively from a signal strength level of the anti-Stokes line.